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Abstract: Lung cancer is the leading cause of cancer related deaths
in the United States. It is estimated that in 2008 there were 215,000
new diagnoses of lung cancer and 163,000 deaths. Despite emerging
technologies for potential early diagnosis and discovery of novel
targeted therapies, the overall 5-year survival remains a disappoint-
ing 15%. Explanations for the poor survival include late presentation
of disease, a lack of markers for early detection, and both phenotypic
and genotypic heterogeneity within patients of similar histologic
classification. To further understand this heterogeneity and thus
complexity of lung cancer, investigators have applied various tech-
nologies including high throughput analysis of both the genome and
proteome. Such approaches have been successful in identifying
signatures that may clarify molecular differences in tumors, identify
new targets, and improve prognostication. In the last decade, inves-
tigators have identified a new mode of gene regulation in the form
of noncoding RNAs termed microRNAs (miRNAs or miRs). First
determined to be of importance in larval development, microRNAs
are approximately 19–22 nucleotide single stranded RNAs that
regulate genes by either inducing mRNA degradation or inhibiting
translation. MiRNAs have been implicated in several cellular pro-
cesses including apoptosis, development, proliferation, and differ-
entiation. By regulating hundreds of genes simultaneously, miRNAs
have the capacity for regulation of biologic networks. Global alter-
ations in miRNA expression in both solid organ and hematological
malignancies suggest their importance in the pathogenesis of dis-
ease. To date, both in vivo and in vitro studies in lung cancer
demonstrate a dysregulation of miRNA expression. Furthermore,
investigators are beginning to identify individual targets and path-
ways of miRNAs relevant to lung tumorigenesis. Thus, miRNAs
may identify critical targets and be important in the pathogenesis of
lung cancer.
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Lung cancer remains the number one cause of cancerrelated deaths in the United States.1 The consistent poor
5-year survival underscores the need for novel modalities for
early detection, prognostication and targeted therapies. Suc-
cessful application of targeted therapies such as epidermal
growth factor receptor inhibition further supports the impor-
tance of understanding the molecular heterogeneity in lung
cancer. Analysis of the genome has partially clarified this
heterogeneity by identifying “signatures” for diagnosis and
prognosis as well as biologic targets. Given that patterns of
mRNA expression may not reflect posttranscriptional modi-
fications, evaluations of the proteome are equally critical to
understanding disease pathogenesis and heterogeneity. Until
recently, studies that rely on high throughput platforms have
been limited by lack of reproducibility and small cohort
size.2–4 The molecular events that lead to lung cancer devel-
opment and progression may be dependent upon multiple
biologic pathways. Therefore, approaches integrating multi-
ple platforms to detect pathways or biologic network depen-
dence in lung cancer are important.
Approximately 15 years ago, investigators first deter-
mined in Caenorhabditis elegans that noncoding RNAs were
relevant to larval development.5 Now referred to as microRNAs
(miRNAs or miRs), these noncoding RNAs have the capacity
for simultaneous regulation of hundreds to thousands of
genes. In fact, in silico analysis suggests that miRNAs may be
responsible for the regulation of up to one third of the
genome.6 MiRNAs are crucial to several biologic processes
including proliferation, apoptosis, development and cellular
differentiation.7 To date, over 800 miRNAs have been iden-
tified in mammals, yet their biologic relevance and functional
targets remain largely unknown. Deregulation in miRNA
expression in several malignancies compared with normal
tissue and their frequent location in fragile chromosomal
regions supports their relevance to malignancy.7 MiRNAs
have the capacity to function as either oncogenes or tumor
suppressors.8 Currently, miRNAs are being investigated
across several solid and hematological malignancies as bi-
omarkers for diagnosis and prognosis of disease.
We are now witnessing a growing body of literature
focused on the role of miRNAs in lung cancer. Studies that
both examine global changes in miRNA within lung tumors
and those that have focused on the effects of individual
miRNAs on lung cancer cell phenotype suggest miRNAs are
involved in lung tumor development and progression and
may potentially serve as biomarkers for diagnosis and prog-
nosis. The review presented will provide an overview of
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miRNA biogenesis, targeting and regulation and offer a
perspective on the emerging role of miRNAs in lung cancer.
miRNA Biogenesis/Targeting
Generation of mature miRNAs requires multiple steps
(Figure 1). To our knowledge, miRNA biogenesis and tar-
geting derives from invertebrate models, however, many of
the proteins are evolutionary conserved throughout evolution
and have similar functions in mammals.9 Initially, a large
primary (pri)-miRNA approximately 100 nucleotides (nt) in
length is transcribed by RNA polymerase II.10 Within the
nucleus, the pri-miRNAs are bound to double-stranded RNA-
binding domain (dsRBD) protein. In invertebrates, Pasha or
Partner of Drosha, whereas in humans DiGeorge syndrome
critical region gene 8 (DGCR8) binds to the pri-miRNA. A
complex containing DGCR8, the pri-miRNA and an univer-
sal RNase III endonuclease, RNASEN, (Drosha in inverte-
brates) facilitates the processing of the pri-miRNA to smaller
approximately 70 nt precursor miRNA (premiRNA) mole-
cules.9,11–13 The premiRNAs form an imperfect stem loop
structure. These are then transported to the cytoplasm by a
protein complex consisting of Exportin 5 and Ran GTPase.14
Once in the cytoplasm, a premiRNA processing complex
containing a second RNase III endonuclease, Dicer, and
transactivating response RNA-binding protein is formed to
cleave the premiRNA to double stranded approximately 22 nt
miRNA molecules.13 The miRNA is then separated into two
single stranded molecules; the antisense strand is incorpo-
rated in the RNA-induced silencing complex (RISC) through
its interaction with Argonaute (AGO) proteins, while the
other strand is degraded. Ago proteins bind to the 3 end of
the RNA and serve to align and stabilize the miRNA:mRNA
duplex. It seems that there is a strong bias for the association
of specific AGO proteins and small RNA subclasses. In
plants, the asymmetry of the 5 end of the miRNA dictates
which Ago protein associates with the small RNA molecule,
whereas in invertebrates structural features of the premiRNA
dictate the binding of specific AGO proteins.15 The precise
mechanisms for AGO-mediated miRNA loading to RISC in
mammals have yet to be determined in mammals and remain
the subject of intense investigation.
Although simplistic in concept that the AGO proteins
and additional components of RISC are important in the
formation of miRNA:mRNA duplex, this alone is not suffi-
cient to predict whether translational repression or degrada-
tion of mRNA targets occur. Conserved base-pairing between
the 3 untranslated region (UTR) of the mRNA and the “seed
sequence” located in the 5 end of the miRNA also have an
important function.16 Through evaluation of the minimal
requirements for miRNA:mRNA interactions, Brennecke et
al.17 identified two categories of target sites; the 5-dominant
sites that require little to no support from the 3 miRNA end
for function because of a high degree of complimentary and
the 3-compensatory sites that generally have sufficient com-
plimentarity to the 5 end of the miRNA. Interestingly,
3-compensatory sites may not necessarily increase efficacy
of interaction and function.18 There are four types of 5-
dominant interaction sites: 6mer, 7mer-m8, 7mer-A1, and
8mer.18 The 6-mer site matches perfectly to the seed sequence
(2–7 nt), while the 7mer-m8 also matches these nucleotides
with additional nucleotide in the 8th position. The 7mer-A1
matches the seed sequence which is augmented by an Ala in
the first position of the miRNA. Lastly, the 8mer is a com-
bination of the two 7mer sites and is comprised of a match
seed sequence with the Ala in the first position and the
matched 8th position of the miRNA. When the 8mer is the
sole site present in the 3 UTR of an mRNA target, deregu-
FIGURE 1. miRNA Biogenesis: miRNA are transcribed as a
large primary (pri)-miRNA which are approximately 100 nu-
cleotides (nt) in length. Pri-miRNAs are bound to double-
stranded RNA-binding domain (dsRBD) protein. In inverte-
brates, Pasha or Partner of Drosha, whereas in humans
DiGeorge syndrome critical region gene 8 (DGCR8) binds to
the pri-miRNA. DGCR8, the pri-miRNA and a universal
RNase III endonuclease, RNASEN, (Drosha in invertebrates)
facilitates the processing of the pri-miRNA to a smaller ap-
proximately 70 nt precursor miRNA (premiRNA) molecules
These are then transported to the cytoplasm by the nuclear
transmembrane Ran GTP-dependent transported Exportin 5.
Once in the cytoplasm, a premiRNA processing complex
containing a second RNase III endonuclease, Dicer, and a
transactivating response RNA-binding protein (TRBP) is
formed to cleave the premiRNA to double stranded 22 nt
miRNA molecules. The miRNA is then separated into two
single stranded molecules; the antisense strand is incorpo-
rated in the RNA-induced silencing complex (RISC) through
its interaction with Argonaute (AGO) proteins, while the
other strand is degraded. Ago proteins bind to the 3 end of
the RNA and serve to align and stabilize the miRNA:mRNA
duplex. The mature miRNA then targets either the 5 or
3UTR based on complimentartity.
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lation of the mRNA target is optimal. Notably, multiple sites
in the 3 UTR of the targeted mRNA are better than one.17–20
However, cooperation and spacing between these sites are
also important factors.18 The number of mismatches between
the miRNA and it target dictate the end result. If perfect
complimentarity exists, then generally the target is degraded
through ubiquitination. Imperfect matches mainly predict
inhibition of protein translation. In some cases, the perfect
match of one miRNA is not sufficient to degrade its target but
rather multiple miRNAs are required to bind the 3 UTR for
a full effect. Given the ubiquitous nature of miRNA/mRNA
targeting, several prediction databases have been developed
based on in silico analysis. Many of these score the free-
energy generated between 5 and 3 base-pairing, consider
phylogentic conservation, and/or limit target identification by
specific 5–interaction sites. For example, TargetScan
(http://www.targetscan.org/) considers matches in the 3 UTR for
only 7mer and 8mer interactions sites.18,20,21 The Sanger
Database (http://microrna.sanger.ac.uk/targets/v5) uses the
miRanda algorithm which weighs 5 miRNA complementary
in the seed sequence, thermodynamic calculations for the
RNA duplex, and conservation across species.22,23 Recently,
the miRDB database/MirTarget2 (http://mirdb.org/miRDB)
was developed using a machine learning approach to analyze
miRNA targets that are conserved and nonconserved across
species. Comparison of these databases using a specific
dataset indicated that the MirTarget2 performed similarly to
TargetScan.24 These bioinformatic tools are very useful in
providing cues on the function of a particular miRNA. The
predicted targets generated from these or other databases
should then be validated experimentally. Using luciferase
assays, by cloning the 3-UTR of target gene into a luciferase
reporter gene downstream and cotransfection with miRNA to
observe the inhibition, is the standard method to confirm the
direct interaction between miRNA and target genes.24 West-
ern blotting or in situ hybridization can be used to confirm the
interaction at protein expression level for miRNA and target
protein localization.
There are several high-throughput approaches to quan-
tify miRNAs in tissue samples but the gold standard is
unclear. cDNA oligonucleotide arrays have become a stan-
dard global scale technique for miRNA profiling.25 MiRNA
microarrays hybridize at a lower melting temperature com-
pared with traditional cDNA arrays, therefore, probe design is
critical. Polymerase chain reaction (PCR) arrays also provide
another high-throughput approach to detect miRNA in a plate
form.26 Cloning of all miRNAs is another technique mainly
used to identify miRNAs and counting the number of se-
quenced miRNAs in a library also provides estimation of
miRNA distribution in a specific tissue.27
Northern blotting using high percentage of urea-acryl-
amide gels was initially one of the primary modalities used to
detect individual small RNAs. An advantage of Northern
blotting is that it can simultaneously identify both observe
precursor and mature miRNA. Real time PCR has been
successfully used for detecting low copy number precursor
and mature miRNA with high sensitivity and specificity.
Stem-loop reverse transcription (RT-PCR) which provides
primers and probe binding sites by incorporating elongated
stem-loop RT primer can be used for accurate miRNA quan-
tification.28 In situ hybridization can provide the quantifica-
tion and the distribution of miRNA simultaneously29 (Figure
2). Alternatively, bead-based flow cytometric miRNA expres-
sion profiling methods combining xMAP with locked nucleic
acids technology is just emerging. The principle in this
approach is that biotin label total RNA is hybridized with
locked nucleic acid-modified capture probes coupled to
xMAP beads, then a streptavidin-phycoerythrin reporter mol-
ecule is for detection on the Luminex analyser.30
miRNA Regulation
MiRNAs are often conserved across species. Not only
do miRNAs serve as important regulators of gene expression,
but their expression is also regulated by multiple factors. The
genomic organization of miRNAs often dictates translational
control. MiRNAs tend to be located in fragile chromosomal
regions that are susceptible to translocations, microdeletions
and amplifications.31 Allelic loss is a frequent genetic alter-
ation in human lung cancers. Cytogenetic and molecular
analyses have revealed chromosomal deletion on 3p, 8p, 9p,
11p, 13q, 17p, 18q, and 22q.32 In fact, several miRNAs
located in these regions are currently being studied. Most
miRNAs are located in genomic regions distant from anno-
tated genes and encoded in independent transcription units.10
Approximately one quarter of human miRNAs are within
introns of mRNAs in the same orientation as these miRNAs,
suggesting that they are not transcribed from their own
promoters but processed from introns. Other miRNAs are
clustered in the genome and transcribed as a polycistronic
primary transcript, suggesting their functional relationships.
To date, 148 miRNAs have been identified within 51 clus-
ters.33 Each of these clusters contains an upstream promoter
region. For example, the miR-17–92 cluster encodes 7 miRNAs
and is regulated by promoter elements for c-Myc, and E2F1-3
transcription factors.34,35 Dews et al.34 reported that the c-
FIGURE 2. In situ detection of miR-222 in squamous cell
cancer of the lung. MiR-221 and 222 are commonly found
in cancers, and can impact similar targets. MiR-222 was de-
tected in most of the malignant cells of this squamous cell
cancer of the lung using a digoxigenin-tagged LNA probe
(panel A); the signal is blue and the counterstain pink. In
comparison, miR-222 was not evident in the cells of this sec-
tion of the adjacent normal lung (panel B).
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Myc transcription factor up-regulates this cluster leading to
the promotion of angiogenesis in solid tumors. This finding
has led to the hypothesis that increased expression of c-Myc
in malignancies would augment the expression of miRNAs.
Surprisingly, over-expression of c-Myc in B-cell lymphomas
leads to global decrease in miRNAs expression.36 It is pre-
dicted that c-Myc binds promoter elements to inhibit trans-
lation. Another important cluster in tumorigenesis is the let-7
family which is decreased in many malignancies.37 Despite
these clusters being regulated by a promoter, not all the
miRNAs contained within the cluster are similarly expressed,
suggesting a second level of posttranscriptional regulation.38
During embryogenesis, the pri-miRNA for the let-7 cluster is
abundant whereas the premiRNAs and mature miRNAs from
this cluster are absent.39 Newman et al.40 identified highly
conserved nucleotides in the loop regions of the primary
transcript for let-7 cluster to which a Drosha inhibitor binds
preventing the processing of the pri-miRNA.
Tumor suppressors within lung cancer are often sus-
ceptible to epigenetic silencing by methylation.41 The miR-29
family functionally targets DNA methytransferases 3A and -3B,
two key enzymes involved in DNA methylation, and often
up-regulated in several malignancies including lung cancer.42
Reexpression of miR-29s in lung cancer cells restores the
normal DNA methylation patterns and reduced tumor devel-
opment.43 MiRNA expression profiling comparing DNA
methyltransferase deficient cells with normal HCT116 cells
found that miR-124a underwent inactivation by CpG island
hypermethylation in human tumors including lung cancers.44
Investigators have determined that polymorphisms
within the 3UTR of a target mRNA may affect miRNA
functional targeting as well. MiRNAs may also be regulated
by other miRNAs and environmental factors such as hypoxia
and cigarette smoke. For example, miRNAs seem to be
globally altered following cigarette smoke exposure.45,46
However, the mechanisms by which this occurs and biologic
implications for lung tumorigenesis remain to be explored.
miRNA and Lung Cancer Cell Phenotype
Several miRNAs have been implicated in lung cancer
by altering fundamental cellular processes (Table 1) thus
making them attractive candidates as therapeutic targets.
Both miR-221 and miR-222 are up-regulated in TNF-alpha
related apoptosis-inducing ligand cell lines. Silencing of
these miRNAs sensitized resistant cell lines to TRAIL
agents.47 MiR-200c may enhance the initiation of an invasive
phenotype through decreasing the expression of zinc finger
transcription factor transcription factor 8, which is an inhib-
itor of E-cadherin that is a crucial event in epithelial-to-
mesenchymal transition.48 Nasser et al. recently showed that
the muscle enriched miR-1 inhibited both in vitro growth and
survival in non-mall cell lung cancer (NSCLC) cell lines
through functional targeting of several oncogenes including
MET, Pim-1, FoxP1, and HDAC4. In addition, miR-1 sensi-
tized cells to chemotherapeutic mediated apoptosis.49 MiR-21
is overexpressed in several solid malignancies including gli-
oblastoma, breast cancer, and lung cancer. MiR-21 targets
several tumor suppressors including PDCD4 and has anti-
apoptotic properties.50 In lung cancer, increased tumor ex-
pression of miR-21 carried a poor overall survival but did not
correlate with histologic features.51 MiR-126 alters both tu-
mor growth and metastatic potential in breast cancer.52 A
recent investigation suggested that miR-126 may alter lung
cancer cell migratory and invasive capacity through func-
tional targeting of Crk.53
miRNA Biogenesis and Lung Cancer
Global repression of miRNA maturation by targeting
three key components of miRNA processing machinery de-
creased miRNA expression in steady-state miRNA levels and
caused a pronounced transformed phenotype in lung cancer
cells. Impaired processing through in vitro targeting of Dro-
sha, DGCR8 and Dicer resulted in accelerated colony forma-
tion and growth in soft agar and in vivo tumor development.54
Karube et al.,55 demonstrated in a cohort of 67 lung cancer
patients that reduced tumor expression of Dicer predicted a
poor post resection prognosis independent of disease stage.
Chiosea et al.56 reported a transient increase in Dicer expres-
sion in both atypical adenomatous hyperplasia and bronchoal-
veolar carcinoma followed by a steady decrease in expression
with more advanced invasive adenocarcinoma. This would
indicate that abrogation of global miRNA processing pro-
motes tumorigenesis.
Let-7
Let-7 was the first miRNA reported to be aberrantly
expressed in human lung cancer.57 The RAS 3-UTR contains
multiple let-7 complementary sites making it a functional
target.58 HMGA2, another oncogene in a variety of tumors
including lung cancers and mesenchymal tumors, is also a
predicted target of let-7.59 Although both RAS and HMGA2
are let-7 targets, K-Ras seems to be stronger than HMGA2 in
rescuing let-7g mediated tumor suppression.60 Overexpres-
sion of let-7 in the A549 cell line inhibited cell growth and
reduced cell cycle progression and division.61 In a murine
model of K-Ras(G12D) induced lung cancer let-7g signifi-
TABLE 1. MiRNA Implicated in Lung Cancer
miRNA Function Target Gene Reference
miR-1 Proliferation
apoptosis
MET, Pim-1, FoxP1,
and HDAC4
50
miR-7 EGFR 72
Let-7 Proliferation Cdk6, CDC25,NRAS,
KRAS, HMGA2
61–64
miR-17–92 Angiogenesis
proliferation
Tsp1, CTGF, HIF1 36
miR-21 Proliferation PDCD4 52
miR-29 Demethylation DNMT 3A and 3B 45
miR-126 Invasion CRK 55
miR-128b EGFR 71
miR-200c Epithelial
mesenchymal
transition
TCF 8 50
miR-221,
miR-222
Apoptosis p27 (kip1), Kit 49
miRNA, microRNA; EGFR, epidermal growth factor receptor; CTGF, connective
tissue growth factor; TCF 8, transcription factor transcription factor 8.
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cantly reduced the number, size and volume of murine tumors
and human non-small cell lung xenografts.60 In addition,
intranasal let-7 administration reduced tumor formation in a
similar K-Ras (G12D) model.62 These findings have trans-
lated to human application. For example, analysis of a small
cohort of early in situ bronchioloalveolar carcinomas, well-
differentiated adenocarcinomas and invasive adenocarcino-
mas revealed that let-7 is important to early occurrence in
carcinogenesis but is not related to prognosis.63 Furthermore,
these observations are supported clinically by the correlation
between reduced let-7 expression in 143 resected lung cancer
cases and poor clinical outcome.57
miR-17–92 Cluster
Although Dicer affects miRNA maturation, the miRNA
cluster miR-17–92 is important in lung development and
homeostasis. MiR-17–92 cluster expression is high in embry-
onic development and steadily declines throughout develop-
ment and into adulthood.64 The miR-1792 cluster was first
identified as a potential oncogene in B-cell lymphoma.65 This
Myc-activated miRNA cluster can increase tumor vasculature
and form larger, better-perfused tumors by functionally tar-
geting antiangiogenic thrombosopndin-1 (Tsp1) and connec-
tive tissue growth factor genes.34 In human lung cancers,
particularly small cell carcinoma, miR-17–92 is also over-
expressed and in vitro introduction enhanced cell prolifera-
tion.64 Antisense oligonucletide mediated inhibition of both
miR-17-5p and miR-20a induced apoptosis selectively in lung
cancer cells over-expressing miR-1792, suggesting onco-
genic potential.66
miRNA and Epidermal Growth Factor
The presence of abnormal levels of growth factor and
its receptor can deregulate the normal cell growth process and
initiate cancer. Epidermal growth factor receptor (EGFR) has
increased expression in several malignancies and has become
the focus of targeted therapeutics.67 EGFR induces cancer in
three ways: overexpression of EGFR ligands, amplification of
EGFR, and mutational activation of EGFR.67 Mutations in
the EGFR tyrosine kinase in NSCLC can cause oncogenic
transformation and change the sensitivity to tyrosine kinase
inhibitors such as gefitinib.68 Two recent studies demon-
strated that EGFR may be a functional target of miRNAs.
MiRNA-128b, located on chromosome 3p which is frequently
deleted in lung cancers, directly down-regulated EGFR.69
However, EGFR expression and mutation status did not
correlate with survival outcome, suggesting a minor effect of
this miRNA on EGFR regulation. Webster et al.70 determined
in vitro that EGFR was a functional target of let-7. Let-7 also
altered expression patterns of several other signaling effectors
including protein kinase B (Akt) and extracellular signal
regulated kinase 1/2 (ERK 1/2).70
Polymorphisms and miRNA Expression
Single-nucleotide polymorphisms (SNPs), are major
determinants of variations in disease susceptibility, medica-
tion response and toxicity.71 Thirty-seven SNPs have been
identified in the p53 gene alone.72 The presence of polymor-
phisms in the 3UTR of the target gene may also compromise
the miRNA binding and regulation.73 In addition, SNPs in
premiRNAs can alter miRNA processing, expression, and
binding to target mRNA. The homozygous CC at SNP
rs11614913 in miR-196a2 correlated with survival in individ-
uals with NSCLC.74 This mutation enhanced the processing
of premiRNA to its mature form and affected the miRNA
binding ability to its target mRNA. Sequence regions within
the 3UTR of K-RAS which is a functional target of let-7
contain SNPs as well. Variant alleles within this SNP caused
a 2.3-fold increased risk for NSCLC and in vitro suppression
of let-7 mediated regulation of K-RAS.75
miRNAs Signatures and Lung Cancer
Platforms for global miRNA detection have been
used to identify their involvement in lung carcinogenesis.
Yanaihara et al.76 compared miRNA patterns of expression in
tumor versus adjacent uninvolved lung in 104 cases of lung
cancer. They identified 43 differentially expressed miRNAs
between lung tumors and adjacent uninvolved lung. In addi-
tion, 5 miRNAs (miR-155, 17-3p, let-7a-2, 145, and 21)
predicted prognosis among patients with lung cancer.
Using an RT-PCR platform for miRNA analysis, Yu et
al.37 recently showed that a 5 miRNA signature correlated
with overall disease free survival in a cohort of 122 patients
with NSCLC. In vitro allied studies identified 3 high-risk
miRNAs (miR-137, miR-182*, miR-372) that increased the
invasive capacity in cancer cells while the protective miR-221
decreased invasion.
Another novel approach to identifying miRNA signa-
tures involves examining target genes of lung enriched
miRNAs. In one such study, investigators identified a 17 gene
signature of genes targeted by miR-34b/34c/449 that accu-
rately distinguished adenocarcinomas from squamous cell
and carried a 90% sensitivity in detecting lung cancer in the
airway when combined with cytopathology.77
CONCLUSION
Lung cancer remains a deadly disease that carries a
poor 5-year prognosis. However, studies focused on elucidat-
ing the molecular heterogeneity are proving successful in
identifying novel targets and subcategorizing clinical pheno-
types. MiRNAs represent newly identified molecules that
have the capacity of multiple gene and thus pathways regu-
lation. To date, several studies have suggested that miRNAs
demonstrate discrete patterns of expression in lung cancer
and are likely critical to the pathogenesis of lung cancer.
Therefore, the study of miRNAs in lung cancer may comple-
ment other more established platforms. We still have only a
preliminary understanding of miRNAs and how targeting
both in vitro and murine studies may be translated to human
disease. Several questions remain: What genes regulate
miRNAs? Which miRNAs regulate which genes? What are
the mechanisms of miRNA function? Given the multitude of
genes that may be targeted by a single miRNA, how can
miRNAs be applied as targeted therapies in vivo while
avoiding deleterious effects? With the development of tech-
niques of miRNA cloning, more functional miRNAs related
to lung cancer will be discovered. In addition, the identifica-
tion of miRNAs by noninvasive means (bronchoalveolar
Wu et al. Journal of Thoracic Oncology • Volume 4, Number 8, August 2009
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lavage and peripheral blood) are being studied. MiRNA offer
a promising platform that has the potential to eventually
influence the prevention, diagnosis, prognosis, and therapy
for lung cancer.
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